Showing results (41-50 of 644) with videos related to
Sort By:
Pageof 65
Immunology|April 12, 2005
CD4+ T-cell responses and distribution at the colonic mucosa during Brachyspira hyodysenteriae-induced colitis in pigsRaquel Hontecillas, Josep Bassaganya-Riera, Jennifer Wilson, et al.Journal of Molecular Modeling|June 1, 2010
Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeuticsPinyi Lu, David R Bevan, Stephanie N Lewis, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2024
Immunometabolic Mechanisms of LANCL2 in CD4+ T Cells and Phagocytes Provide Protection from Systemic Lupus ErythematosusAndrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.Journal of Computer-Aided Molecular Design|January 25, 2015
Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligandsStephanie N Lewis, Zulma Garcia, Raquel Hontecillas, et al.Annual Review of Biomedical Data Science|April 16, 2025
The TITAN-X Platform Integrates Big Data, Artificial Intelligence, Bioinformatics, and Advanced Computational Modeling to Understand Immune Responses and Develop the Next Wave of Precision MedicinesRyan Baker, Josep Bassaganya-Riera, Nuria Tubau-Juni, et al.Journal of Medicinal Chemistry|December 10, 2016
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel DiseaseAdria Carbo, Richard D Gandour, Raquel Hontecillas, et al.Inflammatory Bowel Diseases|November 7, 2023
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's DiseaseNuria Tubau-Juni, Raquel Hontecillas, Andrew J Leber, et al.Drug and Chemical Toxicology|October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.Inflammatory Bowel Diseases|July 12, 2023
Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 ActivationNuria Tubau-Juni, Josep Bassaganya-Riera, Andrew J Leber, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2019
Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T CellsAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.Pageof 65